You searched for: cancer
1 to 10 of 38 results
Show
results per page
Matched phrases in profile:
The LACE study is a clinical trial comparing two types of surgery for women with early-stage cancer… Cancer specialists are aware that not only the survival time but also the quality of life is a key… The value of serum CA125 for the development of virtual follow-up strategies for patients with epithelial ovarian cancer: A retrospective study… feMMe: Uterus-preserving treatment of endometrial cancer… Prophylactic surgery and breast cancer… levonorgestrel intrauterrine device (LNG-IUD) to treat endometrial cancer. The next two steps… Professor Obermair is the Director of Queensland Centre for Gynaecological Cancer Research (QCGC… Background: Serum CA125 is routinely used in the follow up of ovarian cancer. The objective of the…
Professor Obermair is the Director of Queensland Centre for Gynaecological Cancer Research (QCGC Research). He is a Professor of Gynaecological Oncology since 2007, a Senior Medical Officer at Royal Brisbane & Women’s Hospital and a Visiting Medical Officer at St Andrews War Memorial Hospital and …
Professor Obermair is an innovative and skilled gynaecologic oncologist, surgical teacher and consumer advocate. His international leadership and research impact was acknowledged in 2020 by the Australian community, when he was awarded an NHMRC Investigator Fellowship Level 2 (2021-25). The national …
Matched phrases in profile:
Primarily endometrial cancer… Comprehensive genetic assessment of the ESR1 locus identifies a risk region for endometrial cancer… Identifying the regulatory targets of common endometrial cancer risk variants… We and our international Endometrial Cancer Association Consortium collaborators have identified… Gynaecological cancer genetics… -enzyme fusion proteins for cancer therapy. He returned to New Zealand to carry out his PhD research… Excessive exposure to estrogen is a well-established risk factor for endometrial cancer (EC…
After completing his BSc and MSc (Hons) at the University of Canterbury (NZ), Dylan worked for five years as a Research Scientist at Antisoma Research Limited (London, UK), developing antibody-enzyme fusion proteins for cancer therapy. He returned to New Zealand to carry out his PhD research into an …
Large numbers of germline genetic variants have been found to associate with disease. A major roadblock in our understanding of how genetics contribute to disease has been a lack of knowledge of the molecular effects of variants. Thus, the aim of my research program is to use genetic analyses to ass …
Matched phrases in profile:
Therapeutic Opportunity in Cancers with Poor Survival… Complex neoantigen prediction in cancers… genome sequencing technologies in biomedical research. In particular large cancer research…
Research officer, Medical Genomics
QIMR Berghofer Medical Research Institute
My research addressed the challenges related to key genomic components in tumour-immune editing variation in cancers with poor survival and predicting the responses to cancer immunotherapies. Characterizing genomic determinants in underlying response and resistance to cancer immunotherapy. Through w …
Matched phrases in profile:
Using published datasets, and tissue donated by Brisbane breast cancer patients, we're trying to… Post-transcriptional regulation of the breast cancer susceptibility gene BRCA1 by Hu Antigen-R… Development of new theranostic agents for metastatic breast cancer surveillance and treatment… Molecular validation of autofluorescence and narrow band imaging of oral cancer resection margins… Most of the time, treatments for early breast cancer successfully prevent metastatic spread, but… Biomarkers of triple-negative breast cancer progression and response to therapy… cancer. Based at Brisbane’s Translational Research Institute, she was recruited by Mater Research… BRCA1 is a breast cancer susceptibility gene that is down-regulated in the majority of cases of…
Dr Jodi Saunus is a senior fellow who specialises in translational research on metastatic breast cancer. Based at Brisbane’s Translational Research Institute, she was recruited by Mater Research in 2022 to help facilitate patient-focused research at the interface of biomedical R&D and clinical pra …
Matched phrases in profile:
leads to diseases and cancer risk or progression. My current research is focused on developing… A potent antagonist of protease-activated receptor 2 that inhibits multiple signaling functions in human cancer cells… Therapeutics for inflammatory diseases and cancers… or pharmacology (animal models of inflammatory diseases, allergies & asthma, cancers… Experimental therapeutics for inflammatory diseases and cancers… , while inhibiting IL-6 secretion in PAR2 expressing MDA-MB-231 breast cancer cells. This research…
Junxian Lim is an accomplished molecular biologist at the Institute for Molecular Bioscience. With a strong background in cell biology, protein biochemistry, and pharmacology, he has established himself in the field. Collaborating with researchers at universities, institutions, as well as internatio …
Matched phrases in profile:
Melanoma is the fourth most common cancer with >11,000 Australians diagnosed each year resulting… transcriptome, methylation) as well as Spatial Profiling to greater understand the early hallmarks of pre-skin cancer development.… Single nucleotide polymorphisms in obesity-related genes and the risk of esophageal cancers… Laser capture microdissection to empower cancer discoveries, improve diagnosis, treatment and outcomes in amyloidosis patients… development a Genomics Atlas of pre-skin cancer lesions. If you are interested to hear… Genomics Atlas of pre-skin cancer lesions… biomarkers for melanoma progression and the development a Genomics Atlas of pre-skin cancer… Epigenetic gene inactivation of tumour suppressor genes underlies several human cancers. The…
Dr Mitchell Stark is a molecular biologist and Group Leader/Senior Research Fellow from the Dermatology Research Centre (DRC) based at the Frazer Institute. His group has extensive experience in microRNA biology and biomarker discovery, next-generation sequencing, bioinformatics, and functional anal …
Matched phrases in profile:
modalities of neoadjuvant therapy – results from the AGITG DOCTOR trial and the cancer evolution biobank… Cancer genetics… Barbour. Dr Brosda was awarded a PhD in bioinformatics and cancer genetics from the… set of 89 esophageal cancer samples. The most hypermethylated tumors showed worse patient survival.…
Dr Sandra Brosda is a Research Fellow within the Surgical Oncology group led by Professor Andrew Barbour.
Dr Brosda was awarded a PhD in bioinformatics and cancer genetics from the University of Queensland in November 2020. Her research focused on biomarker discovery and intra-tumour heterogeneity …
Matched phrases in profile:
We have discovered a new way to alert the immune system to cancer cells and here wish to explore… Major research focus is on RNA interference (RNAi) based gene therapy and cancer therapy. Closely… Inhibition of cervical cancer cell growth in vitro and in vivo with dual shRNAs… Identifying therapeutic targets and developing targeted cancer therapies for cancer stem cells… Novel photodynamic therapy for targeted skin cancer treatment: an integrated bionanotechnology… Rational design and delivery of small RNAs for effective cancer gene therapies… working in the area of using RNAi to treat viral diseases and cancers. He also has a strong background in immunology and vaccine development.… in a cervical cancer model. However, using this vector to carry two copies of the same shRNA or two…
Dr. Wenyi Gu’s early education was conducted in China which include his undergraduate and master’s degrees in veterinary medicine. In 1996, he migrated to Australia and pursued his PhD study in biochemistry & molecular biology at the Australian National University (ANU). After a short period of …
Dr. Gu's research focus is on RNA interference (RNAi) based gene therapy and cancer therapy. Closely associated with this focus, he also interests in subjects such as oncogenes, cancer stem cells, targeted delivery, cancer cell biomarkers, and cancer immunotherapy. His recent research more focuses o …
Matched phrases in profile:
Spatial omics and multiplexed imaging to explore cancer biology… The molecular basis of breast cancer in young women… Nguyen group’s research is focused on understanding cancer complexity at tissue level by… and cancer-immune cells at single-cell resolution and within spatial morphological tissue context… ageing, cancer and an increasing number of identified pathological conditions. Here we show that…
Dr Quan Nguyen is a Group Leader at the Institute for Molecular Bioscience (IMB), The University of Queensland. He is leading the Genomics and Machine Learning (GML) lab to study neuroinflammation and cancer-immune cells at single-cell resolution and within spatial morphological tissue context. His …
Genomics research for the past decade has relied on data from bulk sequencing of dissociated tissues. The problem with this approach is it discards both intercellular variation among cancer cells and spatial information within a tumour. Dr Nguyen's Cancer Spatial Omics (CSO) program applied spatial …
Matched phrases in profile:
Development of novel therapeutics for melanoma and non-melanoma cancer… Hypoxia-induced stress responses in cancer and cancer stem cells… Skin Cancer… ) promotes stress and death of the organism. However, cancer cells have evolved adaptive mechanisms to…
Researcher Biography
Dr Snehlata Kumari is the head of skin inflammation and immunity laboratory at the Frazer Institute, the University of Queensland in Brisbane, Australia. She is a board member of the Australasian Society for Dermatology Research (ASDR).
After PhD and post-doctoral training in …